Want to see RXRX full AI Analyst Report?
Recursion Pharmaceuticals (RXRX) Ratios
4,711 Followers
Recursion Pharmaceuticals Ratios
RXRX's free cash flow for Q3 2026 was $-77.81M. For the 2026 fiscal year, RXRX's free cash flow was decreased by $-407.00K and operating cash flow was $-77.41M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.50 | 3.81 | 4.70 | 5.68 | 11.46 |
| Quick Ratio | 5.50 | 3.81 | 4.70 | 5.68 | 11.46 |
| Cash Ratio | 5.03 | 3.17 | 4.20 | 5.48 | 6.11 |
| Solvency Ratio | -1.63 | -1.03 | -1.60 | -1.06 | -2.64 |
| Operating Cash Flow Ratio | -2.52 | -1.92 | -3.09 | -0.83 | -3.40 |
| Short-Term Operating Cash Flow Coverage | -40.90 | -42.63 | -7019.02 | -861.07 | -1762.38 |
| Net Current Asset Value | $ 469.58M | $ 300.45M | $ 247.87M | $ 354.33M | $ 467.31M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.07 | 0.08 | 0.07 | 0.02 |
| Debt-to-Equity Ratio | 0.07 | 0.10 | 0.11 | 0.10 | 0.02 |
| Debt-to-Capital Ratio | 0.06 | 0.09 | 0.10 | 0.10 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.30 | 1.40 | 1.41 | 1.44 | 1.12 |
| Debt Service Coverage Ratio | -51.30 | -42.57 | -2199.76 | -1497.80 | -57.57 |
| Interest Coverage Ratio | -358.08 | -304.71 | -3608.87 | -4467.76 | -61.92 |
| Debt to Market Cap | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.18 | 0.40 | 0.24 | 0.29 | 0.08 |
| Net Debt to EBITDA | 1.19 | 1.14 | 1.11 | 2.19 | 1.56 |
| Profitability Margins | |||||
| Gross Profit Margin | -61.96% | 23.12% | 2.94% | -21.66% | 100.00% |
| EBIT Margin | -861.11% | -787.26% | -756.75% | -603.36% | -1835.27% |
| EBITDA Margin | -749.03% | -725.24% | -701.13% | -573.74% | -1751.22% |
| Operating Profit Margin | -867.87% | -814.09% | -797.84% | -619.26% | -1827.75% |
| Pretax Profit Margin | -863.53% | -789.93% | -756.97% | -603.50% | -1864.79% |
| Net Profit Margin | -863.35% | -788.02% | -747.71% | -603.50% | -1864.79% |
| Continuous Operations Profit Margin | -863.35% | -788.02% | -747.71% | -603.50% | -1864.79% |
| Net Income Per EBT | 99.98% | 99.76% | 98.78% | 100.00% | 100.00% |
| EBT Per EBIT | 99.50% | 97.03% | 94.88% | 97.46% | 102.03% |
| Return on Assets (ROA) | -43.74% | -32.01% | -50.19% | -34.15% | -30.55% |
| Return on Equity (ROE) | -57.01% | -44.81% | -70.79% | -49.29% | -34.35% |
| Return on Capital Employed (ROCE) | -48.86% | -37.98% | -62.45% | -40.88% | -32.42% |
| Return on Invested Capital (ROIC) | -48.06% | -37.23% | -61.02% | -40.48% | -32.34% |
| Return on Tangible Assets | -64.34% | -48.10% | -58.04% | -34.25% | -30.66% |
| Earnings Yield | -35.23% | -25.01% | -16.01% | -17.69% | -6.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.03 | 1.20 | 14.18 | 14.41 | 1.10 |
| Payables Turnover | 6.68 | 2.09 | 10.77 | 10.53 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.44 | 0.25 | 0.37 | 0.33 | 0.15 |
| Asset Turnover | 0.05 | 0.04 | 0.07 | 0.06 | 0.02 |
| Working Capital Turnover Ratio | 0.13 | 0.13 | 0.11 | 0.08 | 0.03 |
| Cash Conversion Cycle | 65.80 | 130.61 | -8.14 | -9.35 | 331.79 |
| Days of Sales Outstanding | 120.47 | 304.99 | 25.74 | 25.32 | 331.79 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 54.67 | 174.38 | 33.88 | 34.67 | 0.00 |
| Operating Cycle | 120.47 | 304.99 | 25.74 | 25.32 | 331.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.83 | -1.31 | -1.38 | -0.48 | -0.93 |
| Free Cash Flow Per Share | -0.85 | -1.36 | -1.44 | -0.69 | -1.17 |
| Dividend Paid and CapEx Coverage Ratio | -57.48 | -26.23 | -24.07 | -2.24 | -3.99 |
| Capital Expenditure Coverage Ratio | -57.48 | -26.23 | -24.07 | -2.24 | -3.99 |
| Operating Cash Flow Coverage Ratio | -4.77 | -3.31 | -5.68 | -1.64 | -13.82 |
| Operating Cash Flow to Sales Ratio | -4.98 | -6.10 | -6.56 | -2.10 | -15.86 |
| Free Cash Flow Yield | -20.67% | -20.12% | -14.65% | -8.93% | -6.80% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.84 | -4.00 | -6.25 | -5.65 | -15.64 |
| Price-to-Sales (P/S) Ratio | 24.50 | 31.50 | 46.71 | 34.11 | 291.68 |
| Price-to-Book (P/B) Ratio | 1.62 | 1.79 | 4.42 | 2.79 | 5.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.84 | -4.97 | -6.82 | -11.20 | -14.70 |
| Price-to-Operating Cash Flow Ratio | -4.92 | -5.16 | -7.12 | -16.20 | -18.39 |
| Price-to-Earnings Growth (PEG) Ratio | 0.19 | -0.57 | -0.39 | -0.19 | -0.16 |
| Enterprise Value Multiple | -2.08 | -3.21 | -5.55 | -3.75 | -15.09 |
| Enterprise Value | 1.16B | 1.37B | 1.71B | 854.49M | 2.64B |
| EV to EBITDA | -2.08 | -3.21 | -5.55 | -3.75 | -15.09 |
| EV to Sales | 15.60 | 23.25 | 38.94 | 21.53 | 264.31 |
| EV to Free Cash Flow | -3.08 | -3.67 | -5.69 | -7.07 | -13.32 |
| EV to Operating Cash Flow | -3.13 | -3.81 | -5.94 | -10.23 | -16.66 |
| Tangible Book Value Per Share | 1.47 | 2.01 | 1.80 | 2.76 | 3.18 |
| Shareholders’ Equity Per Share | 2.53 | 3.77 | 2.23 | 2.77 | 3.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Revenue Per Share | 0.17 | 0.21 | 0.21 | 0.23 | 0.06 |
| Net Income Per Share | -1.44 | -1.69 | -1.58 | -1.36 | -1.10 |
| Tax Burden | 1.00 | 1.00 | 0.99 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.02 |
| Research & Development to Revenue | 5.69 | 5.34 | 5.50 | 3.92 | 13.53 |
| SG&A to Revenue | 2.36 | 3.03 | 2.53 | 2.06 | 5.77 |
| Stock-Based Compensation to Revenue | 1.49 | 1.39 | 1.22 | 0.70 | 1.48 |
| Income Quality | 0.58 | 0.77 | 0.88 | 0.35 | 0.85 |
Currency in USD
